The complex, neurological, and incapacitating condition known as migraine is also marked by a number of autonomic symptoms. The first line of defence against moderate-to-severe headache episodes is the use of triptans, which are selective 5-HT1B/1D serotonin agonists. In this article, we examine the most recent information on the clinical effectiveness, safety, and tolerability of eletriptan as well as any potential clinically significant medication interactions. Eletriptan, a triptan, has a high tolerability profile and consistently considerable clinical effectiveness in the treatment of migraine, particularly in individuals with cardiovascular risk factors but without coronary artery disease. Along with rizatriptan, zolmitriptan, and injections of sumatriptan, it exhibits the best clinical response. In addition, when compared to the other triptans, eletriptan has the most complicated pharmacokinetic/dynamic profile. Since the hepatic enzyme CYP3A4 is principally responsible for its metabolism, the concurrent administration of CYP3A4-potent inhibitors needs to be carefully considered. The co-administration of serotoninergic medications results in a comparatively low incidence of serotonin syndrome. With the exception of ergot derivatives, which shouldn't be provided with eletriptan, no clinically significant interactions have been discovered between eletriptan and medications used for migraine preventative therapy or other acute medications.

___________________________________________________________________________________

Keywords: Acute Migraine, Efficacy, Eletriptan, Safety.